Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Benedict Kinny‐Köster

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-7040-9725; OpenAlex author ID A5037349515. Sources: OpenAlex.

Their work

Papers
32 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
135
Papers, trials and grants by year

2020: 1 paper · 2021: 4 papers · 2022: 7 papers · 2023: 8 papers · 2024: 6 papers · 2025: 3 papers · 2026: 3 papers

Papers 32

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Preoperative Surgical or Endoscopic Bile Duct Drainage in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006407↗
  3. Informing Decision-making for Transected Margin Reresection in Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: An International Multicenter … Co-author DOI 10.1097/sla.0000000000006532↗
  4. Adjuvant therapy after resection of intraductal papillary mucinous neoplasm-derived pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ctrv.2025.102969↗
  5. Neoadjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006687↗
  6. Incidence and Outcomes of Intraductal Oncocytic Papillary Neoplasm-Derived Pancreatic Cancer Compared with Tubular and Colloid Intraductal Papillary Mucinous N… Co-author DOI 10.1245/s10434-025-17810-y↗
  7. An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer. Co-author DOI 10.1093/jnci/djae166↗
  8. Clinical Relevance of Cancerization of Ducts in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002326↗
  9. Total versus Partial Pancreatectomy in Patients with Pancreatic Cancer Arising from Multifocal or Diffuse Intraductal Papillary Mucinous Neoplasia - A Multicen… Co-author DOI 10.1097/sla.0000000000006538↗
  10. Outcomes in intraductal papillary mucinous neoplasm-derived pancreatic cancer differ from PanIN-derived pancreatic cancer. Co-author DOI 10.1111/jgh.16686↗
  11. Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Du… First author DOI 10.1158/0008-5472.can-23-1660↗
  12. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. First author DOI 10.1200/jco.23.02313↗
  13. Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: A Bi-institutional validated risk classification. Co-author DOI 10.1016/j.ejso.2023.04.009↗
  14. Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000000200↗
  15. Surgical Decision-Making in Pancreatic Ductal Adenocarcinoma: Modeling Prognosis Following Pancreatectomy in the Era of Induction and Neoadjuvant Chemotherapy. First author DOI 10.1097/sla.0000000000004915↗
  16. A Delay in Adjuvant Therapy Is Associated With Worse Prognosis Only in Patients With Transitional Circulating Tumor Cells After Resection of Pancreatic Ductal … Co-author DOI 10.1097/sla.0000000000005710↗
  17. Distal Pancreatectomy With En Bloc Celiac Axis Resection (DP-CAR) for Locally Advanced Pancreatic Cancer: A Safe and Effective Procedure. Co-author DOI 10.1097/sla.0000000000005866↗
  18. Morphology-guided transcriptomic analysis of human pancreatic cancer organoids reveals microenvironmental signals that enhance invasion. Co-author DOI 10.1172/jci162054↗
  19. Resected Early-Onset Pancreatic Cancer: Practices and Outcomes in an International Dual-Center Study. First author DOI 10.1245/s10434-022-12901-6↗
  20. ASO Author Reflections: Outcomes Support Aggressive Surgery for Early-Onset Pancreatic Cancer. First author DOI 10.1245/s10434-022-12948-5↗
  21. Association of Matrix Metalloproteinase 7 Expression With Pathologic Response After Neoadjuvant Treatment in Patients With Resected Pancreatic Ductal Adenocarc… Co-author DOI 10.1001/jamasurg.2022.1362↗
  22. Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. Co-author DOI 10.1007/s00268-022-06667-x↗
  23. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Co-author DOI 10.1016/j.ccell.2022.10.001↗
  24. Cinematic Rendering: Novel Tool for Improving Pancreatic Cancer Surgical Planning. Co-author DOI 10.1067/j.cpradiol.2022.04.001↗
  25. The Impact of the COVID-19 Pandemic on Multidisciplinary Clinics: A High-Volume Pancreatic Cancer Center Experience. Co-author DOI 10.1067/j.cpradiol.2022.05.001↗
  26. Inflammatory Signaling in Pancreatic Cancer Transfers Between a Single-cell RNA Sequencing Atlas and Co-Culture Co-author DOI 10.1101/2022.07.14.500096↗
  27. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an In… Co-author DOI 10.1245/s10434-021-11081-z↗
  28. Ovarian Metastasis from Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s00268-021-06209-x↗
  29. Lymph Node Metastatic Patterns and Survival Predictors Based on Tumor Size in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12325-021-01819-2↗
  30. Periadventitial dissection of the superior mesenteric artery for locally advanced pancreatic cancer: Surgical planning with the "halo sign" and "string sign". First author DOI 10.1016/j.surg.2020.08.031↗
  31. Favorable tumor biology in locally advanced pancreatic cancer-beyond CA19-9. Co-author DOI 10.21037/jgo-20-426↗
  32. Mesoportal bypass, interposition graft, and mesocaval shunt: Surgical strategies to overcome superior mesenteric vein involvement in pancreatic cancer. Co-author DOI 10.1016/j.surg.2020.07.054↗

Closest collaborators

The 25 strongest of 135 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joseph R. Habib · 24 shared papers, 2020–2026 · strength 3.74
  2. Jin Peng He · 21 shared papers, 2020–2025 · strength 3.16
  3. Ammar A. Javed · 19 shared papers, 2020–2026 · strength 3.03
  4. Kelly J. Lafaro · 14 shared papers, 2020–2025 · strength 1.95
  5. Christopher L. Wolfgang · 13 shared papers, 2022–2025 · strength 1.93
  6. Christopher Lee Wolfgang · 12 shared papers, 2020–2026 · strength 1.88
  7. Markus Wolfgang Büchler · 10 shared papers, 2023–2026 · strength 1.82
  8. Martin Loos · 9 shared papers, 2023–2026 · strength 1.65
  9. Lois A. Daamen · 9 shared papers, 2023–2026 · strength 1.64
  10. Izaak Quintus Molenaar · 9 shared papers, 2023–2026 · strength 1.64
  11. Richard Andrew Burkhart · 12 shared papers, 2020–2024 · strength 1.61
  12. Marc G. Besselink · 8 shared papers, 2024–2026 · strength 1.47
  13. Ingmar Florin Rompen · 7 shared papers, 2024–2026 · strength 1.34
  14. William R. Burns · 9 shared papers, 2020–2024 · strength 1.20
  15. Paul C. M. Andel · 6 shared papers, 2024–2026 · strength 1.11
  16. Jun Yu · 8 shared papers, 2021–2024 · strength 1.04
  17. Greg D. Sacks · 5 shared papers, 2024–2026 · strength 0.95
  18. Brady A. Campbell · 5 shared papers, 2024–2026 · strength 0.94
  19. Jing He · 5 shared papers, 2023–2026 · strength 0.92
  20. Sami Shoucair · 6 shared papers, 2021–2023 · strength 0.83
  21. Adrian Theophil Billeter · 4 shared papers, 2024–2026 · strength 0.76
  22. Hjalmar C. van Santvoort · 4 shared papers, 2023–2026 · strength 0.76
  23. Lei Zheng · 6 shared papers, 2022–2024 · strength 0.73
  24. Daniel Brock Hewitt · 4 shared papers, 2024–2025 · strength 0.71
  25. Thilo Hackert · 4 shared papers, 2023–2026 · strength 0.70

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.